MorphoSys AG (MOR) PT Set at €90.00 by Deutsche Bank AG
MorphoSys AG (ETR:MOR) has been given a €90.00 ($107.14) price objective by investment analysts at Deutsche Bank AG in a research report issued to clients and investors on Thursday. The brokerage presently has a “buy” rating on the stock.
MOR has been the subject of a number of other reports. Independent Research GmbH set a €77.00 ($91.67) price objective on shares of MorphoSys AG and gave the company a “buy” rating in a research report on Monday, May 29th. Goldman Sachs Group, Inc. (The) set a €55.00 ($65.48) price objective on shares of MorphoSys AG and gave the company a “neutral” rating in a research report on Thursday. Commerzbank Ag set a €76.00 ($90.48) price objective on shares of MorphoSys AG and gave the company a “buy” rating in a research report on Thursday, August 31st. Berenberg Bank set a €68.00 ($80.95) price objective on shares of MorphoSys AG and gave the company a “buy” rating in a research report on Thursday, May 25th. Finally, J P Morgan Chase & Co restated a “neutral” rating on shares of MorphoSys AG in a research report on Monday, July 17th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of €70.38 ($83.78).
Shares of MorphoSys AG (MOR) traded down 0.76% during mid-day trading on Thursday, hitting €65.25. 4,295 shares of the stock were exchanged. The stock’s market capitalization is €1.89 billion. MorphoSys AG has a 52 week low of €35.72 and a 52 week high of €70.90. The stock’s 50-day moving average is €60.15 and its 200-day moving average is €59.03.
About MorphoSys AG
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related companies with MarketBeat.com's FREE daily email newsletter.